(Total Views: 137)
Posted On: 09/18/2020 10:06:42 AM
Post# of 36567
I would think they probably saw some data because of this:
Since they are funding, I'd think they want to see actual data on it.
Just my thoughts.
100% funding for development, manufacturing and commercial registration of Ii-Key- SARS-CoV-2 prophylactic vaccine against COVID-19 in Malaysia
Milestone payments totaling $17.5 million upon approval by Malaysian Ministry of Health
Contracted royalty of $3 - $4.50 per dose of vaccine
Potential $150 million in GNBT revenues for vaccine sales in Malaysia
Since they are funding, I'd think they want to see actual data on it.
Just my thoughts.
100% funding for development, manufacturing and commercial registration of Ii-Key- SARS-CoV-2 prophylactic vaccine against COVID-19 in Malaysia
Milestone payments totaling $17.5 million upon approval by Malaysian Ministry of Health
Contracted royalty of $3 - $4.50 per dose of vaccine
Potential $150 million in GNBT revenues for vaccine sales in Malaysia
(0)
(0)
